Cebix
La Jolla
About Cebix
Cebix is focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The role of C-peptide will also be explored in type 1 diabetic nephropathy and retinopathy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $101.4M
- Last round: Series Unknown (Nov 2014)
- Website: cebix.com
- Phone: (858) 729-6500
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cebix-3054137 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.